Oncotarget

Research Papers:

A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer

Ke-Jun Liu and Hai-Ying Wu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:22750-22757. https://doi.org/10.18632/oncotarget.4262

Metrics: PDF 740 views  |   HTML 1080 views  |   ?  


Abstract

Ke-Jun Liu1,2, Hai-Ying Wu1

1State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China

2Department of Medical Oncology, Dongguan People’s Hospital, Dongguan, China

Correspondence to:

Hai-Ying Wu, e-mail: liukejunbz@163.com

Keywords: non-small-cell lung cancer (NSCLC), bevacizumab, platinum-based chemotherapy

Received: April 29, 2015     Accepted: May 30, 2015     Published: June 11, 2015

ABSTRACT

Patients with non-small-cell lung cancer (NSCLC) often have an advanced disease when firstly diagnosed. Bevacizumab is a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR). In this study, we retrospectively analyzed the efficacy of cisplatin, pemetrexed, and bevacizumab in previously treated advanced NSCLC. Results showed that the objective response rate(ORR) of this novel regimen is 43%, median progression-free survival (PFS) was 5.2 months (95% CI, 3.7 to 6.7 months) and median overall survival (OS) was 11.4 months (95% CI, 8.8 to 13.9 months). Adverse events were generally mild, ranging from grade 1 to grade 3. In conclusion, the combination of cisplatin, pemetrexed, and bevacizumab obtained promising results in selected patients with NSCLC. Randomized clinical trials are needed to further investigate the efficacy of this regimen.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4262